LVADS IN AMBULATORY PATIENTS CLASS III PATIENT SHOULD UNDERGO LVAD IMPLANTATION
|
|
- Evelyn Ward
- 5 years ago
- Views:
Transcription
1 LVADS IN AMBULATORY PATIENTS CLASS III PATIENT SHOULD UNDERGO LVAD IMPLANTATION Ajith Nair MD Baylor College of Medicine / Texas Heart Institute American Association for Thoracic Surgery Mechanical Circulatory Support Symposium 2018 THE ARGUMENT FOR LVADS IN AMBULATORY HEART FAILURE PATIENTS
2 LVADS IN NYHA CLASS III PATIENTS? It is difficult to make predictions, particularly about the future Danish proverb Nostradamus Mark Twain Niels Bohr Yogi Berra Better three hours too soon than a minute too late. William Shakespeare
3 LVAD IMPLANTATIONS ACROSS PROFILES NYHA CLASS III CLASS IIIB CLASS IV (Ambulatory) CLASS IV (Non-ambulatory) INTERMACS PROFILES % 1.4% 3.0% 14.6% 29.9% 36.4% 14.3% % OF IMPLANTS REVIVE-IT ROADMAP (NON-INOTROPE DEPENDENT)
4 OUTCOMES : INTERMACS PROFILES INTERMACS PROFILE AND OUTCOMES Survival to Discharge Length of Stay Boyle A, et al. J Heart Lung Transplant 2011;30:402 7
5 OUTCOMES : INTERMACS PROFILES POST- FDA APPROVAL STUDY WITH CF- ASSIST DEVICES Survival for INTERMACS 1-3 vs % vs 72% for one year 69% vs 60% for two year Jorde UP, et al. J Am Coll Cardiol 2014;63:1751 7
6 AMBULATORY ADVANCED HEART FAILURE INTERMACS PROFILE SHORTHAND DEFINITION 4 RESTING SYMPTOMS At home on oral therapy but with frequent symptoms of congestion at rest or with any activities of daily living 5 EXERTION INTOLERANT Comfortable at rest but unable to engage in any activity, living predominantly within the house or housebound, but without overt congestion 6 EXERTION LIMITED Comfortable at rest without evidence of fluid overload and able to do some mild activities of daily living, but gets fatigued within a few minutes of any meaningful exertion 7 ADVANCED NYHA CLASS III Clinically stable with a reasonable level of comfortable activity, despite history of previous decompensation that is not recent
7 MEDAMACS MEDAMACS 1-year survival rates of ~ 47% IF ambulatory INTERMACS 4 7 patients were reassessed as early as 1 month after their baseline visit, a sizeable minority had worse INTERMACS profiles (21 %), functional capacity as measured by 6-min walk time (29 %) or worsening HF quality of life (29 %), Stewart GC, Kittleson MM, et al. Circ Heart Fail. 2016;9:e003032
8 MEDAMACS Stewart GC, Kittleson MM, et al. Circ Heart Fail. 2016;9:e003032
9 HYPE CYCLE
10 ROADMAP YEAR-ONE RESULTS Estep J, Starling RC, Horstmanshof DA, et al. J Am Coll Cardiol 2015;66:
11 ROADMAP YEAR-ONE RESULTS Estep J, Starling RC, Horstmanshof DA, et al. J Am Coll Cardiol 2015;66:
12 ROADMAP YEAR-ONE RESULTS Estep J, Starling RC, Horstmanshof DA, et al. J Am Coll Cardiol 2015;66:
13 ROADMAP YEAR-ONE RESULTS Estep J, Starling RC, Horstmanshof DA, et al. J Am Coll Cardiol 2015;66:
14 ROADMAP YEAR-ONE RESULTS Estep J, Starling RC, Horstmanshof DA, et al. J Am Coll Cardiol 2015;66:
15 ROADMAP YEAR-ONE RESULTS Estep J, Starling RC, Horstmanshof DA, et al. J Am Coll Cardiol 2015;66:
16 ROADMAP 2-YEAR OUTCOMES SURVIVAL : AS TREATED Starling RC, Estep J, Horstmanshof DA, et al. J Am Coll Cardiol HF 2017;5:518 27
17 SURVIVAL : INTENTION-TO-TREAT ROADMAP 2-YEAR OUTCOMES Starling RC, Estep J, Horstmanshof DA, et al. J Am Coll Cardiol HF 2017;5:518 27
18 ROADMAP 2-YEAR OUTCOMES NYHA CLASS : CHANGES Starling RC, Estep J, Horstmanshof DA, et al. J Am Coll Cardiol HF 2017;5:518 27
19 CUMMULATIVE ADVERSE EFFECTS ROADMAP 2-YEAR OUTCOMES 5 patients
20 ROADMAP 2-YEAR OUTCOMES RISK BENEFIT ANALYSIS Starling RC, Estep J, Horstmanshof DA, et al. J Am Coll Cardiol HF 2017;5:518 27
21 ROADMAP TAKE AWAY Differences in the primary endpoint between LVAD and OMM were primarily due to the use of delayed LVADs in the OMM group. LVAD SURGERY LVAD ADVERSE EFFECTS FUNCTIONAL IMPROVEMENT HR-QOL Intention-to-treat analysis suggests no mortality penalty for either early or delayed use of LVADs in these patients, indicating that factors beyond survival are paramount to decision-making surrounding LVAD implantation in this population.
22 ADVANCED NYHA CLASS III PATIENT INABILITY TO TOLERATED GDMT RISK SCORES: SEATTLE HEART FAILURE HEART FAILURE SURVIVAL SCORE HEARTMATE RISK SCORE HOSPITALIZATIONS FOR HEART FAILURE REDUCED 6MWT (<300m) ADVANCED NYHA CLASS III CARDIORENAL CRT NON-RESPONDERS FRAILTY REDUCED PEAK OXYGEN CONSUMPTION (<14ml/kg/min or < 50% predicted)
23 SHARED DECISION-MAKING DECIDE-LVAD Trial Allen, LA, et al. JAMA Intern Med, 2018.
24 REVIVAL REGISTRY EVALUATION OF VITAL INFORMATION FOR VADs IN AMBULATORY LIFE (REVIVAL) Prospective, observational multicenter patient cohort that has completed enrollment of 400 patients with ambulatory advanced HF across 21 sites in the USA 92% of enrollees in profiles 5 7
25 LVAD THERAPY IN CLASS III PATIENTS Survival Functional Status and QOL Adverse Events LVAD INCREASED FUNCTIONAL STATUS INCREASED QOL ADVANCED NYHA CLASS III SHARED DECISION- MAKING OMM LESS ADVERSE EVENTS LESS HOSPITALIZATIONS?
26 LVADS IN NYHA CLASS III PATIENTS? An expert is a person who has found out by his own painful experience all the mistakes that one can make in a very narrow field. Niels Bohr
Lessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward?
Lessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward? Mark S. Slaughter, MD Professor and Chair Department of Cardiovascular and Thoracic Surgery University of Louisville What could
More informationPredicting Outcomes in LVAD Recipients
Predicting Outcomes in LVAD Recipients Sean P. Pinney, MD Director, Advanced Heart Failure & Cardiac Transplantation Professor of Medicine, Cardiology Icahn School of Medicine at Mount Sinai New York,
More informationHFA- ESC criteria for Advanced HF and US Requirements for Destination Therapy
HFA- ESC criteria for Advanced HF and US Requirements for Destination Therapy ESC- HFA criteria for Adv-HF Severe symptoms of HF (NYHA class III or IV) with episodes of fluid retention and/or peripheral
More informationWHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine
WHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine Disclosures Data Safety Monitoring Board SOPRANO (J&J), EVALUATE-HF
More informationIs it time to consider a HEARTMATE LEFT VENTRICULAR ASSIST DEVICE (LVAD)?
Is it time to consider a HEARTMATE LEFT VENTRICULAR ASSIST DEVICE (LVAD)? A treatment for advanced heart failure. LAURA HeartMate II LVAD Recipient What is HEART FAILURE? Heart failure sometimes called
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More informationLIVING A MORE ACTIVE LIFE. with the HeartMate 3 LVAD for the treatment of advanced heart failure RON. Recipient
LIVING A MORE ACTIVE LIFE with the HeartMate 3 LVAD for the treatment of advanced heart failure RON HeartMate 3 LVAD Recipient What is HEART FAILURE? Heart failure sometimes called a weak heart occurs
More informationMechanical Circulatory Support in the Management of Heart Failure
Mechanical Circulatory Support in the Management of Heart Failure Feras Bader, MD, MS, FACC Associate Professor of Medicine Director, Heart Failure and Transplant Cleveland Clinic Abu Dhabi Chairman, Heart
More informationHEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM. HeartMate II Left Ventricular Assist Device
HEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM HeartMate II Left Ventricular Assist Device HeartMate II Left Ventricular Assist Device UNPARALLELED REAL-WORLD EXPERIENCE Over 25,000 heart failure patients
More informationHEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU
HEARTMATE 3 WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU HEARTMATE 3 with Full MagLev Flow Technology HEARTMATE 3 DELIVERS UNPRECEDENTED * SURVIVAL AND SAFETY OUTCOMES **1 LANDMARK SURVIVAL
More informationVentricular Assist Devices for Permanent Therapy: Current Status and Future
Ventricular Assist Devices for Permanent Therapy: Current Status and Future Prospects Francis D. Pagani MD PhD Professor of Cardiac Surgery University of Michigan April 28 th, 2012 Disclosures NHLBI and
More information2018 Update on Heart Failure Management. Where we are today.
2018 Update on Heart Failure Management Where we are today. Mitchell Saltzberg, MD Medical Director Comprehensive Heart Failure and Transplant Program HEART FAILURE 1 Current State of Heart Failure 5.7M
More informationMechanical assist patient selection, device selection, and outcomes
Mechanical assist patient selection, device selection, and outcomes Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine
More informationAdvanced Heart Failure: Patient Identification and Treatment Options. Donald Haas, MD, MPH Abington - Jefferson Health Abington, PA
Advanced Heart Failure: Patient Identification and Treatment Options Donald Haas, MD, MPH Abington - Jefferson Health Abington, PA Disclosures I have received honoraria from Thoratec Corporation/St. Jude
More informationHEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM
HEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM A New Milestone in LVAD Therapy HeartMate 3 Left Ventricular Assist Device Introducing the new HEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY HeartMate 3 LVAD
More informationAcute Circulatory Support Should We or Shouldn t We?
Acute Circulatory Support Should We or Shouldn t We? Navin K. Kapur, MD, FACC, FSCAI Assistant Professor, Division of Cardiology Director, Acute Circulatory Support Program Director, Interventional Research
More informationVentricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation
Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Objectives Current rationale behind use of MCS Patient Selection Earlier?
More informationThe Counter HF Clinical Study for Heart Failure
The Counter HF Clinical Study for Heart Failure CAUTION: C-Pulse is an investigational device. It is limited by Federal (or United States) Law to investigational use only. 13-111-B Agenda Heart Failure
More informationCHANGING THE WAY HEART FAILURE IS TREATED. VAD Therapy
CHANGING THE WAY HEART FAILURE IS TREATED VAD Therapy VAD THERAPY IS BECOMING AN ESSENTIAL PART OF HEART FAILURE PROGRAMS AROUND THE WORLD. Patients with advanced heart failure experience an impaired quality
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationRisk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana Advanced Heart Failure, Transplant, & Mechanical Circulatory Support Relevant Financial Relationship
More informationNew Trends and Indications for LVADs
New Trends and Indications for LVADs Mark S. Slaughter, MD Professor and Chief Division of Thoracic and Cardiovascular Surgery University of Louisville Natural History of Heart Failure 100 10 Class III
More informationCase (Coding Nightmare) Current Dilemmas in Heart Failure : Closing the Gap between Clinical Care and Coding. Current Dilemmas in Heart Failure :
Current Dilemmas in Heart Failure : Closing the Gap between Clinical Care and Coding Interim Vice Chair for Clinical Affairs Department of Medicine, University of Florida 1 2 Case (Coding Nightmare) 69
More informationMechanical support of the failing heart: Will heart transplantation become obsolete? Charles Lindbergh
William Pierce, MD What ever happened to the artificial heart? Mechanical support of the failing heart: Will heart transplantation become obsolete? Dan M. Meyer, MD The 20 th Annual Donald and Lois Roon
More informationNovel Devices for End-Stage Heart Failure
Novel Devices for End-Stage Heart Failure Lynne Warner Stevenson No conflicts of interest Off-label assist devices and expanded indications will be discussed Devices for End-Stage Heart Failure New definitions
More informationLVADs as a long term or destination therapy for the advanced heart failure
LVADs as a long term or destination therapy for the advanced heart failure Prof. Davor Miličić, MD, PhD University of Zagreb School of Medicine Department of Cardiovascular Diseases University Hospital
More informationLVADs as Destination Therapy: When Best Practice Criteria Meets the Real World
LVADs as Destination Therapy: When Best Practice Criteria Meets the Real World Farooq Sheikh, M.D., FACC Advanced Heart Failure Program MedStar Washington Hospital Center Disclosure I have no relevant
More informationTri-City Cardiology Consultants FIFTH ANNUAL SYMPOSIUM
Tri-City Cardiology Consultants FIFTH ANNUAL SYMPOSIUM Faculty Disclosure Banner Baywood Medical Center -Chief of Staff FIFTH ANNUAL SYMPOSIUM NYHA class III-IV symptoms Clinical signs of fluid retention
More informationKEYWORDS: mechanical support; ventricular assist device; cardiac transplantation; destination therapy; patient selection
http://www.jhltonline.org High early event rates in patients with questionable eligibility for advanced heart failure therapies: Results from the Medical Arm of Mechanically Assisted Circulatory Support
More informationWHEN TO REFER FOR ADVANCED HEART FAILURE THERAPIES
WHEN TO REFER FOR ADVANCED HEART FAILURE THERAPIES Mrudula R Munagala, M.D., FACC CO- Director Heart Failure & Circulatory Support Program OklahomaHeart.com Heart Failure Prevalence Heart Failure affects
More informationChristopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine (adj.) Duke University Editor
New Strategies in the Management of Acute and Advanced Heart Failure Christopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine (adj.) Duke University
More informationWHAT S NEW IN HEART FAILURE
WHAT S NEW IN HEART FAILURE Drugs, Devices and Diagnostics John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine Eastern Virginia Medical School
More informationTranslating Device and Mechanical Support Guidelines to ACHD Research. Timothy M. Maul, CCP, PhD Perfusionist Sr. Research Scientist
Translating Device and Mechanical Support Guidelines to ACHD Research Timothy M. Maul, CCP, PhD Perfusionist Sr. Research Scientist Disclosures No financial disclosures May discuss off-label or investigational
More informationCandidate Selection for Long Term VAD
6th Saudi Heart Failure Symposium Riyadh - December 9, 2017 Candidate Selection for Long Term VAD AMMAR CHAUDHARY, MBCHB, FRCPC Consultant Cardiologist Advanced Heart Failure Department of Cardiology King
More informationAdvances in Advanced Heart Failure Therapies. Disclosures. Management Algorithm for Patients in Cardiogenic Shock
Advances in Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center May 20, 2013 Joseph G. Rogers, M.D. Associate Professor
More informationVAD come Destination therapy nell adulto con Scompenso Cardiaco
VAD come Destination therapy nell adulto con Scompenso Cardiaco Francesco Santini Division of Cardiac Surgery, IRCCS San Martino IST University of Genova Medical School, Italy Heart Transplantation is
More informationEnd Stage Heart Failure - Time to Bring the Hammer Down
End Stage Heart Failure - Time to Bring the Hammer Down Eric R. Skipper, MD, FACS Chief, Adult Cardiovascular Surgery Surgical Director of Cardiac Transplantation and Mechanical Circulatory Support 2 3
More informationJournal of the American College of Cardiology Vol. 60, No. 1, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 60, No. 1, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.031
More informationCARDIOMEMS HF SYSTEM HOW TO STAY ABOVE HEART FAILURE: TALKING TO YOUR PATIENT ABOUT THE
CARDIOMEMS HF SYSTEM HOW TO STAY ABOVE HEART FAILURE: TALKING TO YOUR PATIENT ABOUT THE CARDIOMEMS HF SYSTEM This overview of clinical workflow best practices and patient talking points is based on in-depth
More informationKeynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?
Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor
More informationMEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES
MEDICAL POLICY PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationHeart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA
Heart Failure with Reduced EF Dino Recchia, MD, FACC, FHFSA Heart Failure HF is the end phenotype of almost all CV disorders Complex clinical syndrome resulting from any structural or functional impairment
More informationDerivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: the EUROMACS-RHF Risk Score Osama I.I. Soliman, MD, PhD, FACC,
More informationStatus of Implantable VADs
Status of Implantable VADs John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict of Interest Statement
More informationCurtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J
Exercise-based cardiac rehabilitation for people with ventricular assist devices: Associate Professor Andrew Maiorana School of Physiotherapy and Exercise Science, Curtin University; Advanced Heart Failure
More informationWhat Is Best Care for Patients with End stage heart failure?
What Is Best Care for Patients with End stage heart failure? Jin Joo Park, MD Cardiovascular Center, Department of Internal Medicine Bundang Hospital NYHA Class Class Patient Symptoms I No limitation of
More informationDevice Therapy for Heart Failure
Device Therapy for Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics St Boniface General Hospital,
More informationMechanical Circulatory Support (MCS) in 2017: What is New and Different?
Mechanical Circulatory Support (MCS) in 2017: What is New and Different? Rick Thompson, MD Photo Courtesy of St. Jude, Inc Disclosures Together+Clinic Co-Founder CR Bard Consultant MedlaunchSolutions Co-Founder
More informationModern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies
Modern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies ERIC T. ROME D.O. HEART FAILURE, MECHANICAL ASSISTANCE AND TRANSPLANTATION CVI Left Ventricular Assist Device An
More informationThe Role of Exercise in Management of Patients with Heart Failure
The Role of Exercise in Management of Patients with Heart Failure Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Chair, ACC Prevention of Cardiovascular Disease Leadership Council and Section Director,
More information3/2/2017. Identifying the Patient for Advanced Therapies. Why is Identifying the Adv HF patient important? CHF Stages and Steps of Treatment
Identifying the Patient for Advanced Therapies Cindy Bither Chief NP- Adv HF Program Medstar Heart and Vascular Institute Stage A High risk with no symptoms Stage B Structural heart disease, no symptoms
More informationThe Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?
The Who, How and When of Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center Lebanon, NH May 20, 2013 Joseph G. Rogers,
More informationA Fully Magnetically Levitated Left Ventricular Assist Device. Final Report of the MOMENTUM 3 Trial
A Fully Magnetically Levitated Left Ventricular Assist Device Final Report of the MOMENTUM 3 Trial Mandeep R. Mehra, MD, Nir Uriel, MD, Joseph C. Cleveland, Jr., MD, Daniel J. Goldstein, MD, National Principal
More informationHow do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS
How do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS Rey P. Vivo, MD 1 ; Selim R. Krim, MD 2 ; Jerry D. Estep, MD 3 ; Wissam
More informationNew Advances in the Diagnosis and Management of Acute and Chronic Heart Failure
New Advances in the Diagnosis and Management of Acute and Chronic Heart Failure Deborah Budge, MD Intermountain Healthcare Heart Failure Cardiologist Objectives: State the updates from the ACC 2013 HF
More informationThe role of remote monitoring in preventing readmissions after acute heart failure
The role of remote monitoring in preventing readmissions after acute heart failure October 20, 2017 Randall C Starling MD MPH FACC FAHA FESA FHFSA Professor of Medicine Kaufman Center for Heart Failure
More informationThe Interface of Cardiology and Palliative Medicine
The Interface of Cardiology and Palliative Medicine Nathan Goldstein, MD Associate Professor Hertzberg Palliative Care Institute Brookdale Department of Geriatrics and Palliative Medicine Mount Sinai School
More informationMeasure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Heart Failure (HF) Set Measure ID#: HF-1 Measure Information Form Performance
More informationWhat s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine
What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine Current Guideline of Treatment Asymptomatic Mild/Mod Severe Refractory Correct Cause: Arrhythmias
More informationBurden of Mitral Regurgitation (MR) in the US Why is This Important?
Secondary (Functional) Mitral Regurgitation as a Target for Heart Failure Therapy William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCP Professor of Medicine, Physiology, and Cell Biology Chair of Excellence
More informationSeventh INTERMACS annual report: 15,000 patients and counting
http://www.jhltonline.org INTERMACS ANNUAL REPORT Seventh INTERMACS annual report: 15,000 patients and counting James K. Kirklin, MD, a David C. Naftel, PhD, a Francis D. Pagani, MD, PhD, b Robert L. Kormos,
More informationWhen to implant VAD in patients with heart transplantation indication. Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano
When to implant VAD in patients with heart transplantation indication Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano LVAD strategies In waiting list? Goal Bridge to transplant
More informationMechanical Circulatory Support for Unstable Heart Failure
Mechanical Circulatory Support for Unstable Heart Failure Michael A. Acker, MD William Measey Professor of Surgery Chief of Cardiovascular Surgery University of Pennsylvania Health System O.H. Frazier,
More informationAndrew Civitello MD, FACC
Timing the Transition from Short Term to Long Term Mechanical Circulatory Support Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's
More informationHeart Failure 101 The Basic Principles of Diagnosis & Management
Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence
More informationWhat are the indications for Tricuspid valve repair during LVAD Implant RANJIT JOHN, MD UNIVERSITY OF MINNESOTA
What are the indications for Tricuspid valve repair during LVAD Implant RANJIT JOHN, MD UNIVERSITY OF MINNESOTA Contraindications for LVAD Lack of social support system Nonreversible end organ failure
More informationHeart Failure and Renal Disease Cardiorenal Syndrome
Advanced Heart Failure: Clinical Challenges Heart Failure and Renal Disease Cardiorenal Syndrome 17 th Apr 2015 Ju-Hee Lee, M.D Cardiovascular Center, Chungbuk National University Hospital Chungbuk National
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationCardiac Rehabilitation Program for LVAD Patients. Dr Katherine Fan Consultant Cardiologist Grantham Hospital, Hong Kong SAR
Cardiac Rehabilitation Program for LVAD Patients Dr Katherine Fan Consultant Cardiologist Grantham Hospital, Hong Kong SAR Left Ventricular Assist Devices (LVAD) Improved Survival Following LVAD Implantations
More informationMEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationAtrial Fibrillation and Heart Failure
Date Clinical Title Atrial Fibrillation and Heart Failure Raul Weiss MD, FAHA, FACC, FHRS and CCDS Director, Electrophysiology Fellowship Program Professor of Medicine The Ohio State University Wexner
More informationMedical Therapy after LVAD
Medical Therapy after LVAD Maria Frigerio 2nd Section of Cardiology, Heart Failure & Cardiac Transplant Unit DeGasperis CardioCenter, Niguarda Hospital, Milan, Italy Heart failure therapy in LVAD pts A
More informationCASE STUDIES IN ADVANCED HEART FAILURE
CASE STUDIES IN ADVANCED HEART FAILURE Navin Rajagopalan, MD Director, Congestive Heart Failure Medical Director, Cardiac Transplantation Gill Heart Institute, Cardiovascular Medicine DISCLOSURES NOTHING
More informationManagement of Heart Failure in Adult with Congenital Heart Disease
Management of Heart Failure in Adult with Congenital Heart Disease Ahmed Krimly Interventional and ACHD consultant King Faisal Cardiac Center National Guard Jeddah Background 0.4% of adults have some form
More informationGDMT for percutaneous mitral valve repair
GDMT for percutaneous mitral valve repair Ted Feldman, M.D., MSCAI FACC FESC Evanston Hospital The 11th Annual Innovations & Trends in Cardiovascular Care New Brunswick, NJ October 18 th 2014 Ted Feldman
More informationClinical Case. Female, 62 years January 2016
Clinical Case Female, 62 years January 2016 Dr. Ramón Corbalán H. Facultad de Medicina División de Enfermedades Cardiovasculares Pontificia Universidad Católica de Chile Clinical Hx Background: Ostheoartritis
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationMCSD Pump Thrombosis : Industry Perspective
MCSD Pump Thrombosis : Industry Perspective John B. O Connell MD Vice President, Medical Affairs Thoratec Corporation 1 1 Thoratec Asia Pacific Mechanical Circulatory Support (MCS) Conference Agenda 15-17
More informationเอกราช อร ยะช ยพาณ ชย
30 July 2016 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Disclosure Speaker, CME service: Merck, Otsuka, Servier Consultant, non-cme service: Novartis, Menarini
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationThe COUNTER HF Clinical Study for Heart Failure
The COUNTER HF Clinical Study for Heart Failure CAUTION: C- Pulse is an inves?ga?onal device. It is limited by Federal (or United States) Law to inves?ga?onal use only. It is not available for sale in
More informationHF and CRT: CRT-P versus CRT-D
HF and CRT: CRT-P versus CRT-D Andrew E. Epstein, MD Professor of Medicine, Cardiovascular Division University of Pennsylvania Chief, Cardiology Section Philadelphia VA Medical Center Philadelphia, PA
More informationHeart Failure Therapies State of the Art: 2018
Heart Failure Therapies State of the Art: 2018 Andrew J. Sauer MD Associate Professor of Medicine Division Director Advanced Heart Failure Therapies & Cardiac Transplantation University of Kansas Medical
More informationContinuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical Trial
Continuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical Trial Ranjit John, MD, Yoshifumi Naka, MD, Nicholas G. Smedira, MD, Randall Starling, MD, MPH,
More informationIntroducing the COAPT Trial
physician INFORMATION Eligible patients Symptomatic functional mitral regurgitation 3+ Not suitable candidates for open mitral valve surgery NYHA functional class II, III, or ambulatory IV Introducing
More informationTRATTAMENTO INTERVENTISTICO. Dr. Antonio Sagone
TRATTAMENTO INTERVENTISTICO Dr. Antonio Sagone 1 Heart Failure Prevalence & Prognosis Over 26 million people worldwide suffer from heart failure, a chronic, progressive condition in which the heart muscle
More informationUpdate on Mechanical Circulatory Support. AATS May 5, 2010 Toronto, ON Canada
Update on Mechanical Circulatory Support AATS May 5, 2010 Toronto, ON Canada Disclosures NONE Emergency Circulatory Support ECMO Tandem Heart Impella Assessment Cardiac Function Pulmonary function Valvular
More informationPulmonary Hypertension
Left and Right Heart Support as a Bridge to Cardiac Transplantation in Patients with Pulmonary Hypertension Due to Left Heart Disease Dr. Holger Buchholz Clinical Assistant Professor Division of Cardiac
More informationThe CCS Heart Failure Companion: Bridging Guidelines to your Practice
The CCS Heart Failure Companion: Bridging Guidelines to your Practice Looking for practical answers concerning optimal heart failure care? The CCS Heart Failure Guidelines Companion can help. The Canadian
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationThe Mitral Revolution: Transcatheter Repair (and Replacement?) Going Mainstream
The Mitral Revolution: Transcatheter Repair (and Replacement?) Going Mainstream Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org
More informationAllinaHealthSystem 1
: Definition End-organ hypoperfusion secondary to cardiac failure Venoarterial ECMO: Patient Selection Michael A. Samara, MD FACC Advanced Heart Failure, Cardiac Transplant & Mechanical Circulatory Support
More informationعلم االنسان ما لم يعلم
In the name of Allah, the Beneficiate, the Merciful ق ال هللا تعالي: 5 الدى علم بالق لم 4 علم االنسان ما لم يعلم سورة العلق It is He (Allah), Who has taught by the pen He has taught man which he did not
More informationFifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients
http://www.jhltonline.org SPECIAL FEATURE Fifth INTERMACS annual report: Risk factor analysis from more than 6, mechanical circulatory support patients James K. Kirklin, MD, a David C. Naftel, PhD, a Robert
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationAll in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)
More informationCardiac Resynchronization Therapy Guidelines and Missing Groups
Cardiac Resynchronization Therapy Guidelines and Missing Groups Frank Pelosi, Jr., MD, FACC, FHRS Director, Cardiac Electrophysiology Fellowship Associate Professor of Medicine University of Michigan Health
More informationMinimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F.
Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F. Attizzani, MD UH Harrington Heart and Vascular Institute Interventional Cardiologist/Structural
More information